Allegent Technology Group, of Woodbury, N.Y., appointed Robert Swindell to its board.

Amnis Corp., of Seattle, appointed Howard Goldstein senior vice president of sales and marketing.

Avant Immunotherapeutics Inc., of Needham, Mass., appointed Timothy Cooke senior vice president of commercial development.

Biosite Inc., of San Diego, appointed Sarah Gunhouse vice president of sales for the U.S.

The Biotechnology Institute, of Arlington, Va., appointed David Hale, David Holveck and Mark McDade to its board.

Biovail Corp., of Toronto, elected Michael Van Every to its board.

CardioGenesis Corp., of Foothill Ranch, Calif., appointed Joseph Kletzel senior vice president and general manager of the Pacific division.

CeMines Inc., of Evergreen Colo., appointed Wenpei Su director of genomics applications.

Corgentech Inc., of South San Francisco, appointed Thomas Colligan to its board.

Covance Inc., of Princeton, N.J., elected Joseph Herring to its board.

Cytomedix Inc., of Little Rock, Ark., appointed Kelman Cohen, Lawrence Lavery and Linda Phillips to its scientific advisory board.

Genentech Inc., of South San Francisco, appointed Martin Babler vice president, immunology sales and marketing; Karen McCormick vice president, specialty therapeutics sales and marketing; and promoted Vince Anicetti vice president, product portfolio management; and Charles Johnson to vice president, clinical biotherapeutics.

Guilford Pharmaceuticals Inc., of Baltimore, appointed William Spengler executive vice president and chief financial officer.

Halozyme Therapeutics Inc., of San Diego, appointed Gerhard Baumgartner to its scientific advisory board.

Incara Pharmaceuticals Corp., of Research Triangle Park, N.C., appointed Michael Lewis, Chris Rallis and Peter Suzdak to its board.

InfaCare Pharmaceutical Corp., appointed Robert Vukovich chairman, and Digby Barrios, Edward Breslow, William Crouse, Marilyn Lloyd, Wendy Shusko, James Ueberroth and Richard Vietor to its board.

InforMedix Inc., of Rockville, Md., appointed Alexander Miller to its scientific advisory board.

IsoTis OrthoBiologics, of Irvine, Calif., appointed Pieter Wolters CEO.

KV Pharmaceuticals Co., of St. Louis, appointed Terry Hatfield, David Van Vliet and David Hermelin to its board.

No Comments